HTG Molecular Diagnostics Inc (HTGM) Given “Buy” Rating at HC Wainwright
HTG Molecular Diagnostics Inc (NASDAQ:HTGM)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Thursday. They currently have a $5.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 54.80% from the company’s current price.
Other equities research analysts have also issued research reports about the stock. Rodman & Renshaw started coverage on shares of HTG Molecular Diagnostics in a research note on Monday, August 22nd. They set a “buy” rating and a $5.00 target price on the stock. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. HTG Molecular Diagnostics presently has a consensus rating of “Buy” and a consensus target price of $5.25.
Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) traded up 4.19% during midday trading on Thursday, hitting $3.23. 7,105,654 shares of the stock traded hands. The firm’s market capitalization is $22.77 million. HTG Molecular Diagnostics has a 52 week low of $2.03 and a 52 week high of $6.22. The company’s 50-day moving average is $2.46 and its 200 day moving average is $2.65.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/htg-molecular-diagnostics-inc-htgm-given-buy-rating-at-hc-wainwright.html
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its earnings results on Tuesday, August 9th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by $0.03. Analysts anticipate that HTG Molecular Diagnostics will post ($3.58) earnings per share for the current year.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.